Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Low Back Pain Overview | 8 | 1 |
| Therapeutics Development | 9 | 1 |
| Pipeline Products for Low Back Pain Overview | 9 | 1 |
| Low Back Pain Therapeutics under Development by Companies | 10 | 2 |
| Low Back Pain Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Low Back Pain Products under Development by Companies | 15 | 1 |
| Low Back Pain Companies Involved in Therapeutics Development | 16 | 20 |
| Adynxx, Inc. | 16 | 1 |
| Aestus Therapeutics, Inc. | 17 | 1 |
| Array BioPharma Inc. | 18 | 1 |
| Axsome Therapeutics Inc | 19 | 1 |
| Boehringer Ingelheim GmbH | 20 | 1 |
| Egalet Corporation | 21 | 1 |
| Frontier Biotechnologies Co., Ltd | 22 | 1 |
| Gador S.A. | 23 | 1 |
| Grunenthal GmbH | 24 | 1 |
| Hisamitsu Pharmaceutical Co., Inc. | 25 | 1 |
| Immune Pharmaceuticals Inc. | 26 | 1 |
| KPI Therapeutics, Inc. | 27 | 1 |
| MD Biosciences GmbH | 28 | 1 |
| Mesoblast Limited | 29 | 1 |
| Nektar Therapeutics | 30 | 1 |
| Orion Oyj | 31 | 1 |
| Pacira Pharmaceuticals, Inc. | 32 | 1 |
| Pfizer Inc. | 33 | 1 |
| Stayble Therapeutics AB | 34 | 1 |
| Sun Pharma Advanced Research Company Ltd. | 35 | 1 |
| Low Back Pain Therapeutics Assessment | 36 | 10 |
| Assessment by Monotherapy Products | 36 | 1 |
| Assessment by Combination Products | 37 | 1 |
| Assessment by Target | 38 | 2 |
| Assessment by Mechanism of Action | 40 | 2 |
| Assessment by Route of Administration | 42 | 2 |
| Assessment by Molecule Type | 44 | 2 |
| Drug Profiles | 46 | 34 |
| (loxoprofen + methocarbamol) Drug Profile | 46 | 1 |
| AB-001 Drug Profile | 47 | 1 |
| ARRY-954 Drug Profile | 48 | 1 |
| ATX-09002 Drug Profile | 49 | 1 |
| AYX-2 Drug Profile | 50 | 1 |
| bupivacaine Drug Profile | 51 | 2 |
| cebranopadol Drug Profile | 53 | 3 |
| dexmedetomidine hydrochloride Drug Profile | 56 | 2 |
| Drug for Chronic Low Back Pain Drug Profile | 58 | 1 |
| HP-3150 Drug Profile | 59 | 1 |
| IG-8801 Drug Profile | 60 | 1 |
| lidocaine hydrochloride Drug Profile | 61 | 2 |
| MD-22 Drug Profile | 63 | 1 |
| MPC-06ID Drug Profile | 64 | 3 |
| NKTR-181 Drug Profile | 67 | 3 |
| oxycodone hydrochloride ER Drug Profile | 70 | 2 |
| SPARC-1401 Drug Profile | 72 | 1 |
| tanezumab Drug Profile | 73 | 3 |
| U-2902 Drug Profile | 76 | 2 |
| zoledronic acid Drug Profile | 78 | 2 |
| Low Back Pain Dormant Projects | 80 | 2 |
| Low Back Pain Discontinued Products | 82 | 1 |
| Low Back Pain Product Development Milestones | 83 | 4 |
| Featured News &Press Releases | 83 | 1 |
| Aug 01, 2016: MesoblastS Full 24-Month Trial Results for Chronic Low Back Pain Presented at Spine Intervention Society Annual Meeting, Receive Award for Best Basic Science | 83 | 1 |
| Jun 22, 2016: Frontier Biotech Reports Primary Endpoint Met in Phase 2 Trial of AB001 In Chronic Low Back Pain | 84 | 1 |
| Feb 29, 2016: Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms | 84 | 1 |
| Feb 25, 2015: Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain | 85 | 2 |
| Appendix | 87 | 2 |
| Methodology | 87 | 1 |
| Coverage | 87 | 1 |
| Secondary Research | 87 | 1 |
| Primary Research | 87 | 1 |
| Expert Panel Validation | 87 | 1 |
| Contact Us | 87 | 1 |
| Disclaimer | 88 | 1 |